We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.40 | 1.25 | 1.25 | 1.25 | 592,472 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/5/2018 22:10 | ADVFN do not ban You can choose to filter/ignore him. Remember in his own words he says : "Do not reply derampers. They want to turn board into an arguefest". So anyone who replies to him you are feeding the troll and he thinks you are stupid and weak for doing so. | the stigologist | |
10/5/2018 22:08 | What you're worried about is the realisation of the FACTS I have presented. The fact you want to 'ban' me to hide said facts and probably peddle the lies most of the rampers of this share do is more disingenuous. Nothing I have said is 'negative' unless you think telling the truth and correcting others lies is 'negative'. What you really class as negative is 'any thing you don't like to hear'. | davevt | |
10/5/2018 18:26 | Fool there's plenty of counter arguments to your absolute drivel but I've seen enough of your droning on and on to know they are wasted on you | hms_trader | |
10/5/2018 18:13 | Excellent, another waffler with no clue decides to shut up when he can't counter an argument... | davevt | |
10/5/2018 17:32 | This 500 pound dave chats so much garbage, not even going to waste my time responding | hms_trader | |
10/5/2018 14:43 | why would there be any new entrants? How is pyc ahead of the market when it only does dosage modelling for tumor drugs, when all it's competitors do modelling for design, and dosage, for tumors and hundreds of other diseases. All of these companies are years ahead of pyc who are modelling based on 20 year old tech. Trust me, no one is going to copy what pyc do. The relevance of the patents expiring is it doesn't give pyc any unique IP when people are saying 'they could be bought out'. Come on... | davevt | |
10/5/2018 14:19 | Doesn't matter if the patents have expired as that's no longer the USP, rather it's the data that was acquired since which allowed PYC to fine tune their algos. Any new entrant to the market that replicates the algo will still have a long development curve to acquire the years of data PYC have from the work they've done with their partners, without which they pose no real threat as a formulae is nothing without the right inputs. In this sense PYC is still years ahead if the competition in this field for whom there is a significant barrier to entry. | hms_trader | |
10/5/2018 10:49 | Looking in the wrong place. Thanks for sharing. Will save this one for the toilet! Took a senekot last night, first timer ! LolBring the joy :) | margic | |
10/5/2018 10:21 | I'm surprised you couldn't as they are both on the pyc website. www.physiomics-plc.c | davevt | |
10/5/2018 09:55 | All happened between 2002 & 2004 on the patent front. I do give you this, I can't find the patent numbers after a 10 min search, which in thirsty in 2018 should be enough time. | margic | |
10/5/2018 09:54 | Or chart the story so far again.... | margic | |
10/5/2018 07:59 | I think it's you who needs to research.Wayward. | margic | |
09/5/2018 23:37 | And I don't understand what you mean by 'half expect some results soon'. Results from what? It doesn't matter what Merck's results are with their trial, you're not invested in Merck. If you mean what is the result of pycs modelling? Then they give Merck a model, and we already know how much that costs and we already know in advance what we are getting for it. If it matters to you how well Merck have done with their cancer drug, it failed lung and stomach cancer trials in Feb this year. | davevt | |
09/5/2018 23:31 | Margic, I don't know why you're getting excited 'now' about clinical trials with Merck, pyc were doing clinical trials with them, not pre clinical, in 2015. Check the 3rd March 2015 rns. | davevt | |
09/5/2018 22:42 | Yes, that's correct, 20 years. It's priority filing date was 1996. | davevt | |
09/5/2018 21:28 | Follow the VT clinical clues. What the Merck deal will be all about. Clinicals, nice ring to it that. Think we can half expect some results from that soon imo. | margic | |
09/5/2018 21:15 | Unless you know otherwise? | siddle | |
09/5/2018 21:15 | Patents are 20 years. | siddle | |
09/5/2018 19:32 | I wasn't no. | margic | |
09/5/2018 19:24 | Are you aware the patents for systemCell have now expired. It has no true worth now. And yes it may well do clinical trials. But they are years apart. Like I said it takes years to develop a new drug. | davevt | |
09/5/2018 19:14 | It’s worth holding but don’t put everything including kitchen sink into it. | smcl |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions